A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3537021 in Healthy Participants and Patients With Type 2 Diabetes Mellitus
Latest Information Update: 02 Aug 2023
At a glance
- Drugs LY 3537021 (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 26 Jun 2023 Results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 16 Dec 2021 Status changed from active, no longer recruiting to completed.
- 03 Nov 2021 Status changed from recruiting to active, no longer recruiting.